AstraZeneca PLC (AZN)vsStevanato Group SpA (STVN)
AZN
AstraZeneca PLC
$188.41
+1.47%
HEALTHCARE · Cap: $284.30B
STVN
Stevanato Group SpA
$18.39
-0.27%
HEALTHCARE · Cap: $4.98B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4923% more annual revenue ($60.44B vs $1.20B). AZN leads profitability with a 17.2% profit margin vs 11.7%. AZN appears more attractively valued with a PEG of 1.38. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
STVN
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$188.41
$6.16 discount
Margin of Safety
+64.0%
Fair Value
$43.34
Current Price
$18.39
$24.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Premium valuation, high expectations priced in
2.9% earnings growth
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : STVN
The strongest argument for STVN centers on Debt/Equity, Price/Book.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : STVN
The primary concerns for STVN are P/E Ratio, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while STVN is a value play — different risk/reward profiles.
STVN carries more volatility with a beta of 0.78 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 46/100), backed by strong 17.2% margins and 12.5% revenue growth. STVN offers better value entry with a 64.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Stevanato Group SpA
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stevanato Group SpA (STVN) is a premier global supplier of advanced drug delivery systems, catering to the pharmaceutical and biotechnology industries with innovative, high-quality glass and polymer packaging solutions for injectable medications. With a strong focus on quality, sustainability, and the integration of cutting-edge technology, the company is strategically positioned to capitalize on the increasing demand within the biopharmaceutical sector. Stevanato's commitment to enhancing the efficiency and reliability of drug administration underscores its potential as a compelling investment choice for institutional investors seeking exposure to healthcare innovation and sustainable growth.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?